Compare Crispr Therapeutics AG (CRSP) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Crispr Therapeutics AG trades at $51.11 (market cap $4.97B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.78. Which is the better fit depends on your goals.
| CRSP | USIG | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Fixed Income |
52-Week High | $76.78 | $52.69 |
52-Week Low | $44.34 | $50.50 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
USIG trades at $50.50, down 0.4% with bearish technical signals from moving averages but oversold RSI readings. The ETF shows consistent dividend distributions with three payments scheduled for mid-2026. Short interest surged 63.4% in April 2026, indicating increased bearish sentiment among traders despite the investment-grade corporate bond focus.
The ETF faces headwinds from rising short interest and bearish technical momentum, though oversold conditions suggest potential near-term stabilization. Investment-grade corporate bond exposure provides relative safety, but interest rate sensitivity remains a key risk factor for fixed income ETFs in the current market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
